What are the indications, mechanism of action, and alternative therapies for pregabalin (Lyrica)?

Pregabalin (Lyrica): Indications, Mechanism, and Alternatives

FDA-Approved Indications

Pregabalin is FDA-approved for five specific conditions: neuropathic pain from diabetic peripheral neuropathy, postherpetic neuralgia, neuropathic pain from spinal cord injury, fibromyalgia, and as adjunctive therapy for partial-onset seizures in adults 1.

Mechanism of Action

Pregabalin binds with high affinity to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system 1. This binding:

• Reduces calcium-dependent release of pro-nociceptive neurotransmitters in the spinal cord, possibly by disrupting alpha-2-delta-containing calcium channel trafficking and reducing calcium currents
• Modulates descending noradrenergic and serotonergic pathways from the brainstem that control pain transmission in the spinal cord
• Does NOT directly bind to GABA receptors despite being a structural derivative of GABA, though prolonged application increases GABA transporter protein density 1
• Does NOT block sodium channels, opiate receptors, or affect serotonin/dopamine/noradrenaline reuptake 1

Dosing and Pharmacokinetics

Start pregabalin at 50 mg three times daily or 75 mg twice daily, increase to 300 mg/day after 3-7 days, then by 150 mg/day every 3-7 days as tolerated to a maximum of 600 mg/day 2. Key pharmacokinetic advantages over gabapentin include:

• Linear, predictable absorption with ≥90% bioavailability regardless of dose 3
• Rapid absorption with peak levels in 1 hour (vs. 3-4 hours for gabapentin)
• Proportional dose-response relationship (gabapentin shows saturable absorption with decreasing bioavailability at higher doses) 3
• Can be taken with or without food 1
• Requires dose reduction in renal insufficiency 2
• Adequate trial duration: 4 weeks 2

Critical caveat: Doses above 300 mg/day are not consistently more effective but are associated with greater adverse effects 2.

Alternative Therapies for Neuropathic Pain

First-Line Alternatives (Level A/B Evidence)

For neuropathic pain, consider these alternatives based on patient-specific factors:

1. Tricyclic Antidepressants (TCAs) - Secondary amines preferred 2:

   • Nortriptyline or desipramine: Start 25 mg at bedtime, titrate by 25 mg every 3-7 days to maximum 150 mg/day
   • Trial duration: 6-8 weeks with at least 2 weeks at maximum tolerated dose
   • Avoid in patients with cardiac disease or elderly with fall risk

2. SNRIs 2:

   • Duloxetine: Start 30 mg once daily, increase to 60 mg after 1 week (maximum 120 mg/day in divided doses)
   • Venlafaxine: Start 37.5 mg once or twice daily, increase by 75 mg weekly to maximum 225 mg/day
   • Caution with venlafaxine in cardiac disease due to blood pressure increases

3. Gabapentin 2:

   • Start 100-300 mg at bedtime or three times daily
   • Titrate by 100-300 mg every 1-7 days as tolerated to maximum 3600 mg/day in 3 divided doses
   • Disadvantage: Requires 2+ months for adequate trial due to nonlinear pharmacokinetics
   • Advantage: Not a controlled substance (pregabalin is Schedule V)

4. Topical Lidocaine 5% Patch 2:

   • Maximum 3 patches daily for 12-18 hours
   • Best for well-localized peripheral neuropathic pain with allodynia
   • Excellent tolerability in elderly due to minimal systemic absorption
   • Unlikely to benefit central neuropathic pain

Second-Line Options (Reserved for First-Line Failures)

1. Opioids 2:
   • Tramadol: Start 50 mg once or twice daily, increase by 50-100 mg every 3-7 days (maximum 400 mg/day; 300 mg/day if >75 years)
   • Morphine, oxycodone: Start 10-15 mg every 4 hours as needed
   • Use only after first-line medication failures due to long-term safety concerns

Condition-Specific Recommendations

For diabetic peripheral neuropathy specifically 4:

• Pregabalin: Level A evidence (established as effective)
• Duloxetine, venlafaxine, amitriptyline, gabapentin, valproate: Level B evidence (probably effective)
• Opioids (morphine, tramadol, oxycodone), capsaicin: Level B evidence

Important Safety Considerations

Monitor for psychiatric adverse effects: Recent evidence highlights risks of psychosis, hallucinations, anxiety, depression, and sexual disinhibition, particularly with 5:

• High doses
• Sudden withdrawal
• Pre-existing psychiatric illness
• History of substance abuse

Most common adverse effects across all trials 6:

• Somnolence (up to 50%)
• Dizziness (up to 49%)
• Headache (up to 29%)
• Led to study withdrawal in up to 32% of patients

Abuse potential: Pregabalin is Schedule V due to misuse risk, especially in patients with opioid use disorder 7. Avoid or use extreme caution in patients with substance abuse history 8.

Withdrawal management: Taper doses gradually rather than abrupt discontinuation to avoid withdrawal symptoms 5.

Clinical Decision Algorithm

1. Start with pregabalin if rapid titration needed and no substance abuse history (reaches therapeutic dose in 1-2 weeks vs. 2+ months for gabapentin) 2
2. Choose duloxetine for diabetic neuropathy with comorbid depression
3. Choose gabapentin if concerned about abuse potential (not controlled) or cost
4. Choose topical lidocaine for localized peripheral neuropathic pain in elderly patients
5. Choose TCAs for patients who failed other first-line agents and have no cardiac contraindications
6. Reserve opioids for refractory cases after multiple first-line failures